跳至主要内容
临床试验/NCT06443333
NCT06443333招募中不适用

National, Multicentric Registry Study on Neuroimmunological Diseases in China

Xuanwu Hospital, Beijing1 个研究点 分布在 1 个国家目标入组 7,000 人开始时间: 2020年12月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
7,000
试验地点
1
主要终点
Annual recurrence rate

研究概览

简要总结

The aim of this study is to establish a real-world clinical neuroimmune disease research cohort, to follow up and observe the prognosis of patients with different subtypes and subgroups, and to provide support for the treatment, early warning, and outcome prediction research of neuroimmune diseases.

详细描述

The purposes of this study are:(1)Establishing a clinical neuroimmune disease research cohort.(2)Collecting the blood, cerebrospinal fluid and other biological samples of the enrolled patients to discover and detect the new neural antibodies, so as to facilitate the diagnosis of related diseases.(3) Conducting in-depth exploration of the Genetic material of patients with neuroimmune diseases and healthy volunteers with second-generation sequencing technology, discovering the pathogenic genes and the mechanism of disease progression.The enrolled patients will be collected Clinical and therapeutic information. Blood and cerebrospinal fluid from the patients will be collected for sequencing analysis and antibody detection. They will also receive the 2-year follow-up with collection of basic clinical information, cognitive function, EDSS score, etc. Healthy volunteers will have their blood collected for sequencing analysis.

Finish the gene sequencing analysis of blood samples from enrolled patients and healthy volunteers to establish the disease gene database and the reference gene database of the healthy population and find the unique expression quantitative trait loci (eQTL) in China, so as to clarify the pathogenic genes and the key mechanism of neuroimmune disease occurrence and development.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Other

入排标准

性别
All
接受健康志愿者

入选标准

  • Patients who diagnosed at Xuanwu Hospital, Capital Medical University with any of the following conditions:
  • Multiple Sclerosis (the criteria followed the Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria)
  • NMO Spectrum Disorder (the criteria followed the Diagnosis and Treatment Guidelines for Optic Neuromyelitis Spectrum Disorders in China 2016)
  • Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (the criteria followed the Consensus of Chinese Experts on Diagnosis and Treatment of Anti-Myelin Oligodendrocyte Glycoprotein Immunoglobulin G Antibody-Associated Diseases)
  • Myasthenia Gravis (the criteria followed the Guidelines for the Diagnosis and Treatment of Myasthenia Gravis in China 2020)
  • Autoimmune Encephalitis (the criteria followed the China Expert Consensus on Diagnosis and Treatment of Autoimmune Encephalitis 2017)
  • Acute Disseminated Encephalomyelitis (the criteria are based on the article titled "Acute disseminated encephalomyelitis" 2007).
  • Healthy adults who underwent a physical examination at the Physical Examination Center of Xuanwu Hospital, Capital Medical University

排除标准

  • Women during pregnancy or lactation.
  • Patients with other neurological diseases or serious mental diseases.
  • Patients with serious liver and kidney function or other important organ dysfunction.
  • Unable to cooperate with follow-up work and venous blood collection due to poor compliance of patients or healthy volunteers, or incomplete clinical and imaging data.

结局指标

主要结局

Annual recurrence rate

时间窗: At 12 and 24 months after enrollment

Whether there is recurrence in patients followed up at 12 and 24 months after enrollment

次要结局

  • Change in serum and CSF autoimmune antibody status(At 6,12,18,24 months after enrollment)
  • Change in Expanded Disability Status Scale scores (EDSS)(At 6,12,18,24 months after enrollment)
  • Change in MRI of head, optic nerve and spinal cord(At 6,12,18,24 months after enrollment)
  • Change in the relative power spectral density(At 6,12,18,24 months after enrollment)
  • Change in Activity of Daily Living Scale (ADL)(At 6,12,18,24 months after enrollment)
  • Changes in Symbol Digit Modalities Test (SDMT)(At 6,12,18,24 months after enrollment)
  • Changes in Montreal Cognitive Assessment Test (MoCA)(At 6,12,18,24 months after enrollment)
  • changes in Mini-Mental Status Exam (MMSE)(At 6,12,18,24 months after enrollment)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验